作为新型的SARS-CoV-2 RdRp抑制剂,发现和优化费纳索皮里丁化
Jianyuan Zhao1, Guoning Zhang1, YaSheng Li2
1Institute of Medicinal Biotechnology, Chinese Academy of Medical Science, Beijing, China.
European journal of medicinal chemistry
|February 25, 2025
概括
费纳索皮里丁化 (PAP) 有效地抑制了SARS-CoV-2的复制,并向病毒RNA依赖RNA聚合酶 (RdRp). 优化的衍生品显示出强大的抗病毒活性,为COVID-19疗法提供了一个有前途的途径.
科学领域:
- 病毒学 病毒学
- 药物发现 药物发现 药物发现
- 药用化学 医学化学
背景情况:
- 严重急性呼吸系统综合征冠状病毒-2 (SARS-CoV-2) 导致COVID-19,这是一个全球性流行病.
- 病毒RNA依赖RNA聚合酶 (RdRp) 是抗病毒开发的保存标.
- 核类比的有效性受到病毒校对机制 (nsp14/nsp10) 的限制.
研究的目的:
- 为了确定SARS-CoV-2复制的新型抑制剂.
- 评估费纳索皮里丁化 (PAP) 和其衍生物作为潜在的抗病毒药物.
- 调查针对SARS-CoV-2 RdRp.p.的作用机制.
主要方法:
- 在体外抗病毒测试以确定疗效 (EC50).
- 对向SARS-CoV-2 RdRp.p的酶抑制试验
- 化合物的化学优化.
- 对外核糖酶 (ExoN) 的耐药性的评估.
主要成果:
- 费纳索皮里丁化 (PAP) 显示出显著的SARS-CoV-2抑制,EC50为5.37μmol/L.
- 帕普直接抑制了SARS-CoV-2 RdRp,其EC50为7.37μmol/L.
- 优化衍生品PAP-22显示增强的抑制 (EC50为1.11μmol/L) 和广泛的抗冠状病毒活性,对ExoN.抗性.
结论:
- PAP及其衍生品是针对RdRp的强有力的SARS-CoV-2抑制剂.
- 这些化合物对病毒校对机制具有抗性.
- 已确定的PAP的安全性和药理动力学特征支持其作为COVID-19临床抗病毒候选人的潜力.
更多相关视频
相关概念视频
Single Nucleotide Polymorphisms-SNPs
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
Drug Discovery: Overview
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
Structure-Activity Relationships and Drug Design
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Antiviral Nucleoside Inhibitors
Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...


